Diffuse neuroendocrine system and mitochondrial diseases: Molecular and cellular bases of pathogenesis, new approaches to diagnosis and therapy

Neuroendocrinology Letters

Volumn 21, Issue 2, 2000, Pages 83-99

  Kvetnoy, Igor M ^a,b,e   Hernández Yago, José ^a   Hernández, José Miguel ^a   Kvetnaia, Tatiana V ^b   Reiter, Russel J ^c   Khavinson, Vladimir Kh ^d  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Saint Petersburg Institute of Bioregulation and Gerontology   (Russian Federation)

^e Laboratory of Cell Organization   (Spain)

Author keywords

Alzheimer's disease; Diffuse neuroendocrine system; Melatonin; Mitochondrial diseases; Neurodegenerative diseases; Neuropeptides; Parkinson's disease

Indexed keywords

BIOGENIC AMINE; CELL PROTEIN; CHAPERONE; CHEMOKINE; NEUROSTEROID; PEPTIDE HORMONE; UBIQUITIN;

CELL COMMUNICATION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NEUROENDOCRINOLOGY; PROTEIN TRANSPORT; REVIEW;

EID: 0343091290     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Budd SL, Nicholls DG. Mitochondria in the life and death of neurons. In: Higgins SJ, editor. Essays in Biochemistry. Vol. 33. Molecular Biology of the Brain. Portland Press 1998; p. 43-52.
2. Neupert W. Protein import into mitochondria. Annu Rev Biochem 1997; 66:863-917.
3. Ramage L, Junne T, Hahne K, Lithgow T, Schatz G. Functional cooperation of mitochondrial protein import receptors in yeast. EMBO J 1993; 12:4115-4123.
4. Hernandez JM, Hernandez CS, Giner CP, Donat V, Hernandez-Yago J. Identification of Ψ3Tom20, a novel processed pseudogene of the human Tom20 gene, and complete characterization of Ψ1Tom20 and Ψ2Tom20. Mol Gen Genet 1999; 262:207-211.
5. Hernandez JM, Giner P, Hernandez-Yago J. Gene structure of the human mitochondrial outer membrane receptor Tom20 and evolutionary study of its family of processed pseudogenes. Gene 1999; 239:283-291.
6. Schapira AHV. Mitochondrial cytopathies. Curr Opin Neurobiol 1993; 3:760-767.
7. Luft R. The development of mitochondrial medicine. Proc Natl Acad Sci USA 1994; 91:8731-8738.
8. Simon DK, Johns DR. Mitochondrial disorders: clinical and genetic features. Annu Rev Med 1999; 50:111-127.
9. Mihara K, Omura T. Cytoplasmic chaperones in precursor targeting to mitochondria: the role of MSF and hsp70. Trends Cell Biol 1996; 6:104-108.
10. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60:619-642.
11. Gale LM, McColl SR. Chemokines: extracellular messengers for all occasions. BioEssaya 1999; 21:17-28.
12. Pearse AGE. Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C-cells and calcitonin. Proc Roy Soc B 1968; 170:71-80.
13. Pearse AGE. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969; 17:303-313.
14. Raikhlin NT, Kvetnoy IM. The APUD system (diffuse endocrine system) in normal and pathological states. Physiol Gen Biol Rev 1994; 8(4):1-44.
15. Polak JM, Bloom SR. Immunocytochemistry of the diffuse neuroendocrine system. In: Polak JM, Van Noorden S, editors. Immunocytochemistry: modern methods and applications. Bristol, United Kingdom: John Wright & Sons 1986; p. 328-348.
16. Sundler F, Bottcher G, Ekblad E, Hakanson R. The neuroendocrine system of the gut. Acta Oncol 1989; 283:303-314.
17. Kvetnoy IM, Yuzhakov VV, Raikhlin NT. APUD cells: modern strategy of morpho-functional analysis. Microsc Anal 1977; 48:25-27.
18. Larrson L-I. On the possible existence of multiple endocrine, paracrine and neurocrine messengers in secretory system. Invest Cell Pathol 1980; 3:73-85.
19. Kvetnoy IM, Sandvik AK, Waldum HL. The diffuse neuroendocrine system and extrapineal melatonin. J Mol Endocrinol 1997; 18:1-3.
20. Lynn WS, Wong PKY. Neuroimmunodegeneration: do neurons and T cells use common pathways for cell death. FASEB J 1995; 9:1147-1156.
21. Silver R, Silverman A-J, Vitkovic L, Lederhendler II. Mast cells in the brain: evidence and functional significance. Trends Neurosci 1996; 19:25-31.
22. Dines KC, Powell HC. Mast cell interactions with the nervous system: relationship to mechanisms of disease. J Neuropathol Exper Neurol 1997; 56:627-640.
23. Ciesielski-Treska J, Ulrich G, Taupenot L, Chasserot-Golaz S, Corti A, Aunis D, et al. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J Biol Chem 1998; 273:14339-14346.
24. Price DL. New order from neurological disorders. Nature 1999; 399 (Suppl): A3-A5.
25. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56:321-339.
26. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999; 22:123-144.
27. Merrill JE, Jonakait GM. Interactions of the nervous and immune systems in development, normal brain homeostasis, and disease. FASEB J 1995; 9:611-618.
28. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system I: expression and recognition. Trends Neurosci 1995; 18:83-88.
29. Neumann H, Wekerle H. Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. J Neuropathol Exp Neurol 1998; 57:1-9.
30. Mrak RE, Griffin ST, Graham DI. Aging-associated changes in human brain. J Neuropathol Exp Neurol 1997; 56:1269-1275.
31. Borjigin J, Li X, Snyder SH. The pineal gland and melatonin: molecular and pharmacologic regulation. Annu Rev Pharmacol Toxicol 1999; 39:53-65.
32. Griffin SWT, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54:276-281.
33. Morganti-Kossmann MC, Kossmann T, Wahl SM. Cytokines and neuropathology. Trends Pharmacol Sci 1992; 13:286-291.
34. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system. II. Actions and mechanisms of action. Trends Neurosci 1995; 18:130-136.
35. Price DL, Walker LC, Martin LJ, Sisodia SS. Amyloidosis in aging and Alzheimer's disease. Am J Pathol 1992; 141:767-772.
36. Auld DS, Kar S, Quirion R. β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci 1998; 21:43-49.
37. Selkoe DJ. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8:447-453.
38. Calhoun ME, Wiederhold K-H, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. Nature 1998; 395:755-756.
39. Ueda K, Fukushima H, Maslian E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of a novel component of amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90:11282-11286.
40. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, Rohan de Silva HA, et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14:467-475.
41. Tolnay M, Probst A. Review: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 1999; 25:171-187.
42. Mandelkow E-M, Mandelkow E. Tau in Alzheimer disease. Trends Cell Biol 1998; 8:425-497.
43. Blass JP, Baker AC, Ko L, Sheu RK, Black RS. Expression of "Alzheimer antigens" in cultured skin fibroblasts. Arch Neurol 1991; 48:709-717.
44. Spillantini MG, Goedert M. Tau protein pathology in neuro-degenerative diseases. Trends Neurosci 1998; 21:428-433.
45. Lee VM-Y, Trojanowski Q. Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron 1999; 24:507-510.
46. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 388:839-840.
47. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 1998; 21:516-520.
48. Pallares-Trujillo J, Lopez-Soriano FJ, Argiles JM. The involvement of the ubiquitin system in Alzheimer's disease (review). Int J Mol Med 1998; 2:3-15.
49. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998; 21:249-254.
50. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nature Med 1998; 4:755-757.
51. Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sci 1999; 20:73-78.
52. Asensio VC, Campbell IL. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci 1999; 22:504-512.
53. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268:233-238.
54. Martinus RD, Ryan MT, Naylor DJ, Herd SM, Hoogenraad NJ, Hoj PB. Role of chaperones in the biogenesis and maintenance of the mitochondrion. FASEB J 1995; 9:371-378.
55. Hachiya N, Alam R, Sakasegawa N, Sakaguchi M, Mihara N, Omura T. A mitochondrial import factor purified from rat liver cytosol is an ATP-dependent comformational modulator for precursor proteins. EMBO J 1993; 12:1579-1586.
56. Kang PJ, Ostermann J, Shilling J, Neupert W, Craig EA, Pfanner N. Hsp70 in the mitochondrial matrix is required for translocation and folding of precursor proteins. Nature 1990; 348:137-143.
57. Lithgow T, Ryan M, Anderson RL, Hoj PB, Hoogenraad NJ. A constitutive form of heat-shock protein 70 is located in the outer membranes of mitochondria from rat liver. FEBS Lett 1993; 332:277-281.
58. Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 1997; 94:4526-4531.
59. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94:695-698.
60. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992; 6:2311-2322.
61. Kreutzberg GW. Microglia: a sensor for pathological events in CNS. Trends Neurosci 1996; 19:312-318.
62. Tsutsui K, Ukena K. Neurosteroids in the cerebellar Purkinje neuron and their actions (review). Int J Mol Med 1999; 4:49-56.
63. Koenig HL, Schumacher M, Ferzaz B, Thi AND, Ressouches A, Guennoun R, et al. Progesterone synthesis and myelin formation by Schwann Cells. Science 1995; 268:1500-1503.
64. Papadopoulos V, Guarneri P, Krueger KE, Guidotti A, Costa E. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proc Natl Acad Sci USA 1992; 89:5113-5117.
65. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994; 91:10771-10778.
66. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6:3051-3064.
67. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90:7915-7922.
68. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997; 68:2227-2240.
69. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995; 18:172-176.
70. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995; 9:526-533.
71. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32:804-812.
72. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56:359-384.
73. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262:689-695.
74. Choi DW. Calcium: still center-stage in hypoxic-ishemic neuronal death. Trends Neurosci 1995; 18:58-60.
75. Verkhratsky A, Toescu EC. Calcium and neuronal ageing. Trends Neurosci 1998; 21:2-7.
76. Sastry PS, Rao KS. Apoptosis and the nervous system. J Neurochem 2000; 74:1-20.
77. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 1993; 262:695-700.
78. Davies AM. The bcl-2 family of proteins, and the regulation of neuronal survival. Trends Neurosci 1995; 18:355-358.
79. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75:241-251.
80. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY, Greaves MF. Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 1992; 40:1819-1825.
81. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334-336.
82. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361:365-369.
83. Fadeel B, Zhivotovsky B, Orrenius S. All along the watchtower: on the regulation of apoptosis regulators. FASEB J 1999; 13:1647-1657.
84. Reiter RJ. Comparative physiology: pineal gland. Annu Rev Physiol 1973; 35:305-328.
85. Reiter RJ. The aging pineal gland and its physiological consequences. BioEssays 1992; 14:169-175.
86. Grata LJ, Brown GM. Antibodies to indolealkylamines: serotonin and melatonin. Can J Biochem 1974; 52:196-203.
87. Kvetnoy IM. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histoch J 1999; 31:1-12.
88. Tan DX, Manchester LC, Reiter RJ, Qi WB, Zhang M, Weintraub ST, et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999; 1472:206-214.
89. Pang SF. Dubocovich ML, Brown GM. Melatonin receptors in peripheral tissues: a new area of melatonin research. Biol Signals 1993; 2:177-180.
90. Reiter RJ. Aging and oxygen toxicity: relation to changes in melatonin. Age 1997; 20:201-213.
91. Reiter RJ, Poeggeler B, Tan D-X, Chen L-D, Manchester LC. Antioxidant capacity of melatonin: a novel function not requiring a receptor. Neuroendocr Lett 1993; 15:103-116.
92. Cuzzocrea S, Tan D-X, Costantino G, Mazzon E, Caputi AP, Reiter RJ. The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat. FASEB J 1999; 13:1930-1938.
93. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann NY Acad Sci 1998; 854:410-424.
94. Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Chen LD, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26:497-502.
95. Acuna-Castroviejo D, Coto-Montes A, Monti MG, Ortiz GG, Reiter RJ. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60:23-29.
96. Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriquez C. Melatonin prevents apoptosis induced by 6-hydroxy-dopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res 1998; 24:179-192.
97. Efthimiopoulos S, Vassilacopoulou D, Ripellino JA, Tezapsidis N, Robakis NK. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc Natl Acad Sci USA 1996; 93:8046-8050.
98. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998; 18:407-430.
99. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res 1990; 27:576-586.
100. Yew DT, Li WP, Webb SE, Lai HW, Zhang L. Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzhemer patients: a comparison. Exp Gerontol 1999; 34:117-133.
101. Rinne PP, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, Relja M. Neuronal histamine deficit in Alzheimer's disease. Neuroscience 1998; 82:993-997.
102. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77-79.
103. Figlewicz DP, Lacour F, Sipols A. Gastroenteropancreatic peptides and the central nervous system. Annu Rev Physiol 1987; 49:383-395.
104. Brown M, Rivier J, Vale W. Somatostatin: central nervous system actions on glucoregulation. Endocrinology 1979; 104:1709-1715.
105. Reubi JC, Palacios J. Somatostatin and Alzheimer's disease: a hypothesis. J Neurol 1986; 233:370-372.
106. Beal MF, Benoit R, Mazurek MF, Bird ED, Martin JB. Somatostatin-28 (1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Res 1986; 368:380-383.
107. Beal MF. Somatostatin in neurodegenerative illnesses. Metabolism 1990; 39 (9, Suppl 2):116-119.
108. Li WP, Lai HW, Cheng SY, Yew DT. Somatostatin-positive neurons in the different parts of the brain in normal aging and Alzheimer's disease. Biol Signals 1996; 5:343-348.
109. Van Uden E, Veinbergs I, Mallory M, Orlando R, Masliah E. A novel role for receptor-associated protein in Somatostatin modulation: implications for Alzheimer's disease. Neuroscience 1999; 88:687-700.
110. Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987; 8:521-545.
111. Suemaru S, Suemaru K, Hashimoto K, Ogasa T, Hirasawa R, Makino S, et al. Cerebrospinal fluid corticotropin-releasing hormone and ACTH, and peripherally circulating choline-containing phospholipid in senile dementia. Life Sci 1993; 53:697-706.
112. De Souza EB, Whitehouse PJ, Kuhar MJ, Price DLV, Vale WW. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 1986; 319:593-595.
113. Whitehouse PJ, Vale WW, Zweig RMV, Singer HS, Mayeux R, Kuhar MJ, et al. Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. Neurology 1987; 37:905-909.
114. Suemaru S, Hashimoto K, Ogasa T, Hirasawa RV, Makino S, Ota Z, et al. Cerebrospinal fluid and plasma corticotropin-releasing hormone in senile dementia. Life Sci 1991; 48:1871-1879.
115. Chiso E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, et al. Growth hormone secretion in Alzheimer's disease: studies with growth hormone releasing hormone alone and combined with pyridostigmine or arginine. Dementia 1993; 4:315-320.
116. Edvinsson L, Minthon L, Ekman R, Gustafson L. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 1993; 4:167-171.
117. Dysken MW, Falk A, Pew B, Kuskowski M, Krahn DD. Gender differences in TRH-stimulated TSH and prolactin in primary degenerative dementia and elderly controls. Biol. Psychiatry 1990; 28:144-150.
118. Sakanaka M, Shiosaka S, Takatsuki K, Inagaki S, Takagi H, Senba E, et al. Experimental immunohistochemical studies on the amygdalofugal peptidergic (substance P and somatostatin) fibers in the stria terminalis of the rat. Brain Res 1981; 221:231-242.
119. Sakanaka M, Shiosaka S, Takatsuki K, Inagaki S, Hara Y, Kawai Y, et al. Origins of substance P-containing fibers in the lateral septal area of young rats: immunohistochemical analysis of experimental manipulations. J Comp Neurol 1982; 212:268-277.
120. Ljungdahl A, Hokfelt T, Nillson G. Distribution of substance P-like immunoreactivity in the central nervous system of the rat. I. Cell bodies and nerve terminals. Neuroscience 1978; 3:861-943.
121. Ronnekleiv OK, Kelly MJ, Eskay RL. Distribution of immunoreactive substance P neurons in the hypothalamus and pituitary of the rhesus monkey. J Comp Neurol 1984; 224:51-59.
122. Aronin N, Coslovsky R, Leeman SE. Substance P and neurotensin: their role in the regulation of anterior pituitary function. Annu Rev Physiol 1986; 48:537-549.
123. Tsuruo Y, Kawano H, Nishimaya T, Hisano S, Daikoku S. Substance P-like immunoreactive neurons in the tuberoin-fundibular area of rat hypothalamus. Light and electron microscopy. Brain Res 1983; 289:1-9.
124. Jennes L, Stumpf WE, Kalivas PW. Neurotensis: topographical distribution in rat brain by immunohistochemistry. J Comp Neurol 1982; 210:211-224.
125. Kahn D, Abrams GM, Zimmerman EA, Carraway R, Leeman SE. Neurotensin neurons in the rat hypothalamus: an immunocytochemical study. Endocrinology 1980; 107:47-54.
126. Kahn D, Hou-You A, Zimmerman EA. Localization of neurotensin in the hypothalamus. Ann NY Acad Sci 1982; 400:117-131.
127. Ibata Y, Fukui K, Okamura H, Kawakami T, Tanaka M, Obata HL, et al. Co-existence of dopamine and neurotensin in hypothalamic arcuate and periventricular neurons. Brain Res 1983; 269:177-179.
128. Goedert M, Lightman SL, Nagy JI, Marley PD, Emson PC. Neurotensin in the rat anterior pituitary gland. Nature 1982; 298:163-165.
129. Goltermann NR. In vivo biosynthesis of cholecystokinin in hog cerebral cortex. Peptides 1982; 3:101-104.
130. Dumbrille-Ross A, Seeman P. Dopamine receptor elevation by cholecystokinin. Peptides 1984; 5:1207-1212.
131. Lofberg C, Harro J, Gottfries CG, O'eland L. Cholecystokinin peptides and receptor binding in Alzheimer's disease. J Neural Transm Gen Sect 1996; 103:851-860.
132. Brown MR. Central nervous system sites of action of bombesis and somatostatin to influence plasma epinephrine levels. Brain Res 1983; 276:253-257.
133. Everitt BJ, Hokfelt T, Terenius L, Tatemoto K, Mutt V, Goldstein M. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience 1984; 11:443-462.
134. Lundberg JM, Saria A, Franco-Cereceda A, Hokfelt T, Terenius L, Goldstein M. Differential effects of reserpine and 6-hydroxydopamine on neuropeptide Y (NPY) and noradrenaline in peripheral neurons. Arch Pharmacol 1985; 328:331-340.
135. Beal MF, Mazurek MF, Chattha GK, Svendsen CN, Bird ED, Martin JB. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Ann Neurol 1986; 20:282-288.
136. Irwin M, Brown M, Patterson T, Hauger R, Mascovich A, Grant I. Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress. FASEB J 1991; 5:3100-3107.
137. Baskin DG, Figlewicz DP, Woods SC, Potte DJ, Dorsa DM. Insulin in the brain. Annu Rev Physiol 1987; 49:335-347.
138. Boyd FT, Clarke DW, Muther TF, Raizada MK. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. J Biol Chem 1985; 260:15880-15884.
139. Rhoads DE, Rocco RJ, Osburn LD, Peterson WA, Raghupathy E. Stimulation of synaptosomal uptake of neurotransmitter amino acids by insulin: possible role of insulin as a neuro-modulator. Biochem Biophys Res Commun 1984; 119:1198-1204.
140. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105:423-438.
141. Tominaga M, Kaneda H, Marubashi S, Kamimura T, Katagiri T, Sasaki H. Synaptosomal localization and release of glucagon-like materials in the rat brain. Brain Res Bull 1984; 12:373-375.
142. Rubanyi GM, Botelho HP. Endothelins. FASEB J 1991; 5:2713-2720.
143. Minami M, Kimura M, Iwamoto N, Arai H. Endothelin-1-like immunoreactivity in cerebral cortex of Alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 1996; 19:509-513.
144. Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease. FASEB J 1998; 12:17-34.
145. Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O, et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J Neuropathol Exp Neurol 1999; 58:803-814.
146. Tan D-X, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Comm 1998; 253:614-620.